Piramal's Neuraceq receives FDA approval for amyloid imaging

03/20/2014 | HealthImaging.com

Piramal Imaging's diagnostic amyloid PET agent F-18 florbetaben, branded as Neuraceq, has been approved by the FDA. Neuraceq is indicated for PET imaging of the brain to estimate beta amyloid plaque density in patients with cognitive impairment who are being evaluated for possible Alzheimer's disease. Piramal Imaging has partnered with IBA Molecular for manufacturing and distribution of Neuraceq.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations